IL-13Rα2 is also known as cancer/testis antigen (CT)19 since it is one of the testis-specific antigens that is overexpressed in a range of solid cancers, and, therefore, it can serve as a potential target for cancer therapy [12,13,14,15]. This evidence concerns the gene IL13RA2 and cancer.